{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:49:47Z","timestamp":1791931787896,"version":"4.3.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"BB and A Miller Foundation"},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2033462"],"award-info":[{"award-number":["GNT2033462"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2009476"],"award-info":[{"award-number":["APP2009476"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2007839"],"award-info":[{"award-number":["GNT2007839"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2018514"],"award-info":[{"award-number":["GNT2018514"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["ECF1376"],"award-info":[{"award-number":["ECF1376"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["TPG 2021\/TPG2114"],"award-info":[{"award-number":["TPG 2021\/TPG2114"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sydney Cancer Partners and Maridulu Budyari Gumal (SPHERE) Cancer CAG","award":["2021\/CBG0002 & 2021\/CBG0003"],"award-info":[{"award-number":["2021\/CBG0002 & 2021\/CBG0003"]}]},{"name":"Melanoma Foundation of the University of Sydney"},{"name":"Charles Perkins Centre Catchlove Sylvan MCR Bridging Fellowship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glycolysis, commonly used by malignant tumors for energy production, results in acidification of the tumor microenvironment (TME) through the secretion and accumulation of lactic acid. Acidosis is a potent inhibitor of immune cell function and may therefore affect T-cell infiltration and the efficacy of immunotherapy. This study aimed to characterize the metabolic tumor microenvironment and its association with lymphocyte distribution in patients with advanced melanoma treated with immune checkpoint blockade (ICB) therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Pre-treatment formalin-fixed, paraffin-embedded metastatic melanoma specimens from 45 patients treated with anti-PD-1\u2009\u00b1\u2009anti-CTLA-4 ICB were included in this study. Patients with progression-free survival (PFS)\u2009\u2265\u20096mo were categorized as responders (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923), while non-responders had a PFS &lt;\u20096mo (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200922). Two custom multiplex immunofluorescence panels were developed to evaluate the expression and distribution of markers of a hypoxic microenvironment (CA9 and HIF1\u03b1), glycolysis (GLUT1 and GLUT3) and vessels (CD31) in relation to melanocytes (SOX10) and T lymphocytes (CD3).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      GLUT1\u2009+\u2009melanoma regions contained significantly lower proportions of CD3\n                      <jats:sup>+<\/jats:sup>\n                      T-cells than GLUT1- regions (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Responders displayed significantly higher proportions of intratumoral T-cells expressing GLUT1 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.049) and GLUT3 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.043) compared to non-responders. CD3\n                      <jats:sup>+<\/jats:sup>\n                      T-cells co-expressing hypoxia-associated markers were present in higher proportions significantly closer to GLUT1\n                      <jats:sup>+<\/jats:sup>\n                      melanoma cells in responders compared to non-responders (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Patients with higher proportions of CD3\n                      <jats:sup>+<\/jats:sup>\n                      T-cells and CD3\n                      <jats:sup>+<\/jats:sup>\n                      CA9\n                      <jats:sup>+<\/jats:sup>\n                      T-cells within the 20\u00a0\u00b5m distance to GLUT1\n                      <jats:sup>+<\/jats:sup>\n                      \u00a0melanoma cells had significantly longer progression-free survival\u00a0(\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0133 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0378, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Together, these findings support the hypothesis that the presence of glycolysis in melanoma (as inferred by increased GLUT expression) may affect the ability of T-cells to infiltrate tumors and function effectively. The results also suggest that the overall proportion and spatial distribution of GLUT\n                      <jats:sup>+<\/jats:sup>\n                      T-cells, including those displaying evidence of adaptation to a hypoxic\/acidic TME, may be relevant for responses to ICB therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03637-8","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T13:16:33Z","timestamp":1768914993000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["GLUT1 expression, lymphocyte distribution and CD3+ T-cell metabolic subsets as predictive markers of response to immunotherapy in advanced melanoma"],"prefix":"10.1186","volume":"45","author":[{"given":"Elizabeth C.","family":"Paver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuba N.","family":"Gide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarwa","family":"Yaseen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cornejo-Paramo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel G.","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines Pires","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Scolyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Wilmott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"3637_CR1","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.4155\/fmc-2021-0071","volume":"13","author":"S Cao","year":"2021","unstructured":"Cao S, Chen Y, Ren Y, Feng Y, Long S. GLUT1 biological function and inhibition: research advances. Future Med Chem. 2021;13:1227\u201343. https:\/\/doi.org\/10.4155\/fmc-2021-0071.","journal-title":"Future Med Chem"},{"key":"3637_CR2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrc.2017.77","volume":"17","author":"C Corbet","year":"2017","unstructured":"Corbet C, Feron O. Tumour acidosis: from the passenger to the driver\u2019s seat. Nat Rev Cancer. 2017;17:577\u201393. https:\/\/doi.org\/10.1038\/nrc.2017.77.","journal-title":"Nat Rev Cancer"},{"key":"3637_CR3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","volume":"21","author":"PS Ward","year":"2012","unstructured":"Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012;21:297\u2013308. https:\/\/doi.org\/10.1016\/j.ccr.2012.02.014.","journal-title":"Cancer Cell"},{"key":"3637_CR4","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","volume":"109","author":"K Fischer","year":"2007","unstructured":"Fischer K, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109:3812\u20139. https:\/\/doi.org\/10.1182\/blood-2006-07-035972.","journal-title":"Blood"},{"key":"3637_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1218297","volume":"2018","author":"F Erra D\u00edaz","year":"2018","unstructured":"Erra D\u00edaz F, Dantas E, Geffner J. Unravelling the interplay between extracellular acidosis and immune cells. Mediators Inflamm. 2018;2018:1218297. https:\/\/doi.org\/10.1155\/2018\/1218297.","journal-title":"Mediators Inflamm"},{"key":"3637_CR6","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/nrc1478","volume":"4","author":"RA Gatenby","year":"2004","unstructured":"Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891\u20139. https:\/\/doi.org\/10.1038\/nrc1478.","journal-title":"Nat Rev Cancer"},{"key":"3637_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12253-017-0363-7","volume":"25","author":"M Dura","year":"2019","unstructured":"Dura M, et al. Expression of Glut-1 in Malignant Melanoma and Melanocytic Nevi: an Immunohistochemical Study of 400 Cases. Pathol Oncol Res. 2019;25:361\u20138. https:\/\/doi.org\/10.1007\/s12253-017-0363-7.","journal-title":"Pathol Oncol Res"},{"key":"3637_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/srep24129","volume":"6","author":"G Cretenet","year":"2016","unstructured":"Cretenet G, et al. Cell surface Glut1 levels distinguish human CD4 and CD8 T lymphocyte subsets with distinct effector functions. Sci Rep. 2016;6:24129. https:\/\/doi.org\/10.1038\/srep24129.","journal-title":"Sci Rep"},{"key":"3637_CR9","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1523\/JNEUROSCI.10-12-03862.1990","volume":"10","author":"SI Harik","year":"1990","unstructured":"Harik SI, Kalaria RN, Andersson L, Lundahl P, Perry G. Immunocytochemical localization of the erythroid glucose transporter: abundance in tissues with barrier functions. J Neurosci. 1990;10:3862\u201372. https:\/\/doi.org\/10.1523\/JNEUROSCI.10-12-03862.1990.","journal-title":"J Neurosci"},{"key":"3637_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/CMR.0000000000000626","volume":"29","author":"KN Ruby","year":"2019","unstructured":"Ruby KN, et al. Diagnostic and prognostic value of glucose transporters in melanocytic lesions. Melanoma Res. 2019;29:603\u201311. https:\/\/doi.org\/10.1097\/CMR.0000000000000626.","journal-title":"Melanoma Res"},{"key":"3637_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.febslet.2004.10.043","volume":"577","author":"E Svastova","year":"2004","unstructured":"Svastova E, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004;577:439\u201345. https:\/\/doi.org\/10.1016\/j.febslet.2004.10.043.","journal-title":"FEBS Lett"},{"key":"3637_CR12","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.3390\/molecules20022323","volume":"20","author":"BP Mahon","year":"2015","unstructured":"Mahon BP, Pinard MA, McKenna R. Targeting carbonic anhydrase IX activity and expression. Molecules. 2015;20:2323\u201348. https:\/\/doi.org\/10.3390\/molecules20022323.","journal-title":"Molecules"},{"key":"3637_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"PH Maxwell","year":"1999","unstructured":"Maxwell PH, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271\u20135. https:\/\/doi.org\/10.1038\/20459.","journal-title":"Nature"},{"key":"3637_CR14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nrd3554","volume":"10","author":"D Neri","year":"2011","unstructured":"Neri D, Supuran CT. Interfering with ph regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov. 2011;10:767\u201377. https:\/\/doi.org\/10.1038\/nrd3554.","journal-title":"Nat Rev Drug Discov"},{"key":"3637_CR15","doi-asserted-by":"publisher","unstructured":"Gide TN, et al. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1\/Anti-CTLA-4 Combined Therapy. Cancer Cell. 2019;35:238\u2013255 e236. https:\/\/doi.org\/10.1016\/j.ccell.2019.01.003.","DOI":"10.1016\/j.ccell.2019.01.003"},{"key":"3637_CR16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.18632\/oncotarget.422","volume":"3","author":"PC McDonald","year":"2012","unstructured":"McDonald PC, Winum JY, Supuran CT, Dedhar S. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget. 2012;3:84\u201397. https:\/\/doi.org\/10.18632\/oncotarget.422.","journal-title":"Oncotarget"},{"key":"3637_CR17","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/01.sla.0000201452.09591.f3","volume":"243","author":"A Driessen","year":"2006","unstructured":"Driessen A, et al. Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg. 2006;243:334\u201340. https:\/\/doi.org\/10.1097\/01.sla.0000201452.09591.f3.","journal-title":"Ann Surg"},{"key":"3637_CR18","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1158\/2326-6066.CIR-18-0657","volume":"7","author":"SC Chafe","year":"2019","unstructured":"Chafe SC, et al. Targeting hypoxia-induced carbonic anhydrase IX enhances immune-checkpoint blockade locally and systemically. Cancer Immunol Res. 2019;7:1064\u201378. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0657.","journal-title":"Cancer Immunol Res"},{"key":"3637_CR19","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1200\/JCO.2013.51.3002","volume":"31","author":"NE Thomas","year":"2013","unstructured":"Thomas NE, et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol. 2013;31:4252\u20139. https:\/\/doi.org\/10.1200\/JCO.2013.51.3002.","journal-title":"J Clin Oncol"},{"key":"3637_CR20","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","volume":"30","author":"F Azimi","year":"2012","unstructured":"Azimi F, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012;30:2678\u201383. https:\/\/doi.org\/10.1200\/JCO.2011.37.8539.","journal-title":"J Clin Oncol"},{"key":"3637_CR21","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1093\/jnci\/81.24.1893","volume":"81","author":"WH Clark Jr.","year":"1989","unstructured":"Clark WH Jr., et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893\u2013904. https:\/\/doi.org\/10.1093\/jnci\/81.24.1893.","journal-title":"J Natl Cancer Inst"},{"key":"3637_CR22","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1200\/JCO.2006.08.9755","volume":"25","author":"RC Taylor","year":"2007","unstructured":"Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol. 2007;25:869\u201375. https:\/\/doi.org\/10.1200\/JCO.2006.08.9755.","journal-title":"J Clin Oncol"},{"key":"3637_CR23","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5","volume":"77","author":"CG Clemente","year":"1996","unstructured":"Clemente CG, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77:1303\u201310. https:\/\/doi.org\/10.1002\/(SICI)1097-0142(19960401)77:7%3c1303::AID-CNCR12%3e3.0.CO;2-5.","journal-title":"Cancer"},{"key":"3637_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02105","volume":"11","author":"F Maibach","year":"2020","unstructured":"Maibach F, Sadozai H, Seyed Jafari SM, Hunger RE, Schenk M. Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma. Front Immunol. 2020;11:2105. https:\/\/doi.org\/10.3389\/fimmu.2020.02105.","journal-title":"Front Immunol"},{"key":"3637_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.pathol.2015.12.006","volume":"48","author":"N Lee","year":"2016","unstructured":"Lee N, Zakka LR, Mihm MC Jr., Schatton T. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology. 2016;48:177\u201387. https:\/\/doi.org\/10.1016\/j.pathol.2015.12.006.","journal-title":"Pathology"},{"key":"3637_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.908612","volume":"13","author":"R van de Ven","year":"2022","unstructured":"van de Ven R, Bifulco CB, Luke JJ, Church SE. Editorial: mechanisms of lymphocyte exclusion in the tumor microenvironment. Front Immunol. 2022;13:908612. https:\/\/doi.org\/10.3389\/fimmu.2022.908612.","journal-title":"Front Immunol"},{"key":"3637_CR27","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","volume":"10","author":"P Bonaventura","year":"2019","unstructured":"Bonaventura P, et al. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019;10:168. https:\/\/doi.org\/10.3389\/fimmu.2019.00168.","journal-title":"Front Immunol"},{"key":"3637_CR28","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1158\/0008-5472.Can-11-1272","volume":"72","author":"A Calcinotto","year":"2012","unstructured":"Calcinotto A, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res. 2012;72:2746\u201356. https:\/\/doi.org\/10.1158\/0008-5472.Can-11-1272.","journal-title":"Cancer Res"},{"key":"3637_CR29","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1659093","volume":"9","author":"TN Gide","year":"2020","unstructured":"Gide TN, et al. Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. Oncoimmunology. 2020;9:1659093. https:\/\/doi.org\/10.1080\/2162402X.2019.1659093.","journal-title":"Oncoimmunology"},{"key":"3637_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159\u201374.","journal-title":"Biometrics"},{"key":"3637_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051862","volume":"7","author":"J Budczies","year":"2012","unstructured":"Budczies J, et al. Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS ONE. 2012;7:e51862. https:\/\/doi.org\/10.1371\/journal.pone.0051862.","journal-title":"PLoS ONE"},{"key":"3637_CR32","doi-asserted-by":"publisher","unstructured":"Cascone T, et al. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab. 2018;27:977\u2013987 e974. https:\/\/doi.org\/10.1016\/j.cmet.2018.02.024.","DOI":"10.1016\/j.cmet.2018.02.024"},{"key":"3637_CR33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2017.03.012","volume":"78","author":"D Massi","year":"2017","unstructured":"Massi D, et al. Baseline \u03b2-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients. Eur J Cancer. 2017;78:70\u201381. https:\/\/doi.org\/10.1016\/j.ejca.2017.03.012.","journal-title":"Eur J Cancer"},{"key":"3637_CR34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231\u20135. https:\/\/doi.org\/10.1038\/nature14404.","journal-title":"Nature"},{"key":"3637_CR35","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1038\/onc.2013.409","volume":"33","author":"Y Dong","year":"2014","unstructured":"Dong Y, et al. Pten functions as a melanoma tumor suppressor by promoting host immune response. Oncogene. 2014;33:4632\u201342. https:\/\/doi.org\/10.1038\/onc.2013.409.","journal-title":"Oncogene"},{"key":"3637_CR36","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","volume":"17","author":"GV Long","year":"2016","unstructured":"Long GV, et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 2016;17:1743\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(16)30578-2.","journal-title":"Lancet Oncol"},{"key":"3637_CR37","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","volume":"22","author":"B Weide","year":"2016","unstructured":"Weide B, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. 2016;22:5487\u201396. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0127.","journal-title":"Clin Cancer Res"},{"key":"3637_CR38","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1731942","volume":"9","author":"S Van Wilpe","year":"2020","unstructured":"Van Wilpe S, et al. Lactate dehydrogenase: a marker of diminished antitumor immunity. Oncoimmunology. 2020;9:1731942. https:\/\/doi.org\/10.1080\/2162402X.2020.1731942.","journal-title":"Oncoimmunology"},{"key":"3637_CR39","doi-asserted-by":"publisher","first-page":"594609","DOI":"10.3389\/fimmu.2020.594609","volume":"11","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Guan XY, Jiang P. Cytokine and chemokine signals of T-cell exclusion in tumors. Front Immunol. 2020;11:594609. https:\/\/doi.org\/10.3389\/fimmu.2020.594609.","journal-title":"Front Immunol"},{"key":"3637_CR40","doi-asserted-by":"publisher","unstructured":"Spranger S, Dai D, Horton B, Gajewski TF. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017;31:711\u2013723 e714, https:\/\/doi.org\/10.1016\/j.ccell.2017.04.003.","DOI":"10.1016\/j.ccell.2017.04.003"},{"key":"3637_CR41","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","volume":"69","author":"H Harlin","year":"2009","unstructured":"Harlin H, et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009;69:3077\u201385. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2281.","journal-title":"Cancer Res"},{"key":"3637_CR42","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1182\/blood-2005-05-1795","volume":"107","author":"E Gottfried","year":"2006","unstructured":"Gottfried E, et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood. 2006;107:2013\u201321. https:\/\/doi.org\/10.1182\/blood-2005-05-1795.","journal-title":"Blood"},{"key":"3637_CR43","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1084\/jem.20092140","volume":"207","author":"SL Jongbloed","year":"2010","unstructured":"Jongbloed SL, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med. 2010;207:1247\u201360. https:\/\/doi.org\/10.1084\/jem.20092140.","journal-title":"J Exp Med"},{"key":"3637_CR44","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1093\/rheumatology\/keab022","volume":"60","author":"E Andreucci","year":"2021","unstructured":"Andreucci E, et al. Glycolysis-derived acidic microenvironment as a driver of endothelial dysfunction in systemic sclerosis. Rheumatology (Oxford). 2021;60:4508\u201319. https:\/\/doi.org\/10.1093\/rheumatology\/keab022.","journal-title":"Rheumatology (Oxford)"},{"key":"3637_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110013","volume":"37","author":"E Matas-Rico","year":"2021","unstructured":"Matas-Rico E, et al. Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8(+) T cells. Cell Rep. 2021;37:110013. https:\/\/doi.org\/10.1016\/j.celrep.2021.110013.","journal-title":"Cell Rep"},{"key":"3637_CR46","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1158\/0008-5472.CAN-17-1624","volume":"78","author":"JH Ha","year":"2018","unstructured":"Ha JH, et al. LPA induces metabolic reprogramming in ovarian cancer via a pseudohypoxic response. Cancer Res. 2018;78:1923\u201334. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1624.","journal-title":"Cancer Res"},{"key":"3637_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041968","author":"L Joshi","year":"2021","unstructured":"Joshi L, et al. Lysophosphatidic acid induces aerobic glycolysis, lipogenesis, and increased amino acid uptake in BV-2 microglia. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22041968.","journal-title":"Int J Mol Sci"},{"key":"3637_CR48","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/s1097-2765(00)00066-6","volume":"6","author":"JC Rathmell","year":"2000","unstructured":"Rathmell JC, Vander Heiden MG, Harris MH, Frauwirth KA, Thompson CB. In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability. Mol Cell. 2000;6:683\u201392. https:\/\/doi.org\/10.1016\/s1097-2765(00)00066-6.","journal-title":"Mol Cell"},{"key":"3637_CR49","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/s1074-7613(02)00323-0","volume":"16","author":"KA Frauwirth","year":"2002","unstructured":"Frauwirth KA, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity. 2002;16:769\u201377. https:\/\/doi.org\/10.1016\/s1074-7613(02)00323-0.","journal-title":"Immunity"},{"key":"3637_CR50","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang CH, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162:1229\u201341. https:\/\/doi.org\/10.1016\/j.cell.2015.08.016.","journal-title":"Cell"},{"key":"3637_CR51","doi-asserted-by":"publisher","first-page":"4476","DOI":"10.4049\/jimmunol.180.7.4476","volume":"180","author":"SR Jacobs","year":"2008","unstructured":"Jacobs SR, et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J Immunol. 2008;180:4476\u201386. https:\/\/doi.org\/10.4049\/jimmunol.180.7.4476.","journal-title":"J Immunol"},{"key":"3637_CR52","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.21873\/anticanres.17199","volume":"44","author":"W Ma","year":"2024","unstructured":"Ma W, Li Z, Wen J, Yan S. The expression and prognostic value of multiple glucose transporters in cutaneous melanoma. Anticancer Res. 2024;44:3747\u201356. https:\/\/doi.org\/10.21873\/anticanres.17199.","journal-title":"Anticancer Res"},{"key":"3637_CR53","doi-asserted-by":"publisher","first-page":"E242","DOI":"10.1152\/ajpendo.90388.2008","volume":"295","author":"IA Simpson","year":"2008","unstructured":"Simpson IA, et al. The facilitative glucose transporter GLUT3: 20 years of distinction. Am J Physiol Endocrinol Metab. 2008;295:E242-253. https:\/\/doi.org\/10.1152\/ajpendo.90388.2008.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"3637_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.976628","volume":"13","author":"E Cribioli","year":"2022","unstructured":"Cribioli E, et al. Enforcing GLUT3 expression in CD8(+) T cells improves fitness and tumor control by promoting glucose uptake and energy storage. Front Immunol. 2022;13:976628. https:\/\/doi.org\/10.3389\/fimmu.2022.976628.","journal-title":"Front Immunol"},{"key":"3637_CR55","doi-asserted-by":"publisher","unstructured":"Hochrein SM, et al. The glucose transporter GLUT3 controls T helper 17 cell responses through glycolytic-epigenetic reprogramming. Cell Metab. 2022;34:516\u2013532 e511. https:\/\/doi.org\/10.1016\/j.cmet.2022.02.015.","DOI":"10.1016\/j.cmet.2022.02.015"},{"key":"3637_CR56","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/s41423-024-01229-8","volume":"21","author":"A Sharma","year":"2024","unstructured":"Sharma A, et al. Glut3 promotes cellular o-GlcNAcylation as a distinctive tumor-supportive feature in Treg cells. Cell Mol Immunol. 2024;21:1474\u201390. https:\/\/doi.org\/10.1038\/s41423-024-01229-8.","journal-title":"Cell Mol Immunol"},{"key":"3637_CR57","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0684","author":"A Venkat","year":"2025","unstructured":"Venkat A, et al. AAnet resolves a continuum of spatially-localized cell states to unveil intratumoral heterogeneity. Cancer Discov. 2025. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0684.","journal-title":"Cancer Discov"},{"key":"3637_CR58","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward NK, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545:175\u201380. https:\/\/doi.org\/10.1038\/nature22071.","journal-title":"Nature"},{"key":"3637_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164026","author":"G Castellani","year":"2023","unstructured":"Castellani G, et al. BRAF mutations in melanoma: biological aspects, therapeutic implications, and circulating biomarkers. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15164026.","journal-title":"Cancers (Basel)"},{"key":"3637_CR60","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1126\/science.1174229","volume":"325","author":"J Yun","year":"2009","unstructured":"Yun J, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science. 2009;325:1555\u20139. https:\/\/doi.org\/10.1126\/science.1174229.","journal-title":"Science"},{"key":"3637_CR61","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s41420-024-02250-6","volume":"10","author":"G Zheng","year":"2024","unstructured":"Zheng G, et al. BAP1 inactivation promotes lactate production by leveraging the subcellular localization of LDHA in melanoma. Cell Death Discov. 2024;10:483. https:\/\/doi.org\/10.1038\/s41420-024-02250-6.","journal-title":"Cell Death Discov"},{"key":"3637_CR62","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1159\/000529818","volume":"66","author":"X Guo","year":"2023","unstructured":"Guo X, et al. A Novel Glycolysis-Related Signature for Predicting the Prognosis and Immune Infiltration of Uveal Melanoma. Ophthalmic Res. 2023;66:692\u2013705. https:\/\/doi.org\/10.1159\/000529818.","journal-title":"Ophthalmic Res"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03637-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03637-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03637-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:51:31Z","timestamp":1781628691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-025-03637-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3637"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03637-8","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, and with ethical approval from the Sydney Local Health District Human Research Ethics Committee (Protocol No. X15-0454 and HREC\/11\/RPAH\/444). Samples were acquired with written informed consent from all patients and the Melanoma Biospecimen Tissue Bank.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R.A.S. has received fees for professional services from MetaOptima Technology Inc., F. Hoffmann-La Roche Ltd., Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, Amgen Inc., Bristol Myers Squibb, Myriad Genetics, and GlaxoSmithKline, SkylineDx BV, and IO Biotech ApS. G.V.L. has served as a consultant advisor for Agenus, Amgen, Array Biopharma, AstraZeneca, Bayer HealthCare Pharmaceuticals Inc, BioNTech SE, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Evaxion Biotech A\/S, GI Innovation Inc, Hexal AG (Sandoz Company), Highlight Therapeutics S.L., IOBiotech, Immunocore Ireland Limited, Innovent Biologics USA Inc, Iovance Biotherapeutics Inc, Merck Sharpe & Dohme, Novartis Pharma AG, OncoSec Medical Australia, PHMR Limited, Pierre Fabre, Regeneron Pharmaceuticals, Scancell Limited, and SkylineDX BV. A.M.M. is on the advisory board of BMS, Merck (MSD), Novartis, Roche, Pierre Fabre and Qbiotics. I.P.S. is on the advisory board of Merck Sharp & Dohme, Regeneron and Strand Therapeutics; has received fees for professional services from Roche, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, and Pierre Fabre; and has had travel support from Bristol Myers Squibb and Merck Sharp & Dohme. M.S.C. has served on advisory boards or as a consultant for Amgen, BMS, Eisai, Ideaya, Merck, Sharp & Dohme (MSD), Nektar, Novartis, Oncosec, Pierre-Fabre, Qbiotics, Regeneron, Roche, Merck, Moderna and Sanofi and received honoraria from BMS, MSD and Novartis. All other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}